Physiologically Based Pharmacokinetic Modelling of Cabozantinib to Simulate Enterohepatic Recirculation, Drug–Drug Interaction with Rifampin and Liver Impairment
Cabozantinib (CAB) is a receptor tyrosine kinase inhibitor approved for the treatment of several cancer types. Enterohepatic recirculation (EHC) of the substance is assumed but has not been further investigated yet. CAB is mainly metabolized via CYP3A4 and is susceptible for drug–drug interactions (...
Збережено в:
| Автори: | , |
|---|---|
| Формат: | Artigo |
| Мова: | Inglês |
| Опубліковано: |
MDPI AG
2021-05-01
|
| Серія: | Pharmaceutics |
| Предмети: | |
| Онлайн доступ: | https://www.mdpi.com/1999-4923/13/6/778 |
| Теги: |
Немає тегів, Будьте першим, хто поставить тег для цього запису!
|